buying, page-19

Hey Rony18,

I read an article a few days ago about the business speculator (I think it was posted in the BNB thread).

The speculator mentioned that you should adopt a strategy of not falling for the company and to take profits.

I guess my only opinion is that yes, the company looks to be on the right track (at least I think it is) and the only way a company like this makes money is from 2 ways:
a. Private equity acquisition - Venture capital
b. Commercialisation

The only reason I haven't invested in FER earlier is because I am in the indication that commercialisation will take several more months. My prediction is March 2009 but I hope I am wrong and it is earlier. Just have been looking at tonnes of these clinical testings for companies like Novartis, Monsanto, SmithKline Glaxo, etc. and they always take longer than hoped.

Reason I bought in at the 30 - 40 cent level is because I anticipate the results from Asia to be out shortly and although I think they may be having problems getting people to not use hair products /damage their hair, the results should be quite favourable.

Shamol : Very sorry for making a passing comment that is potentially deceiving.

I think there are some similarities you may be interested in drawing from Cochlear v Fermiscan when Cochlear was in its initial phase.
1. Cochlear technology was made for people with a disability in hearing. As you may know, the percentage of people needing hearing aid in Australia is less than 5% at the time the technology initiated. (correct me if I am wrong). Not sure about the latest data, but the percentage of women who have been diagnosed with breast cancer is not that high either. This shows that this research is for a specific market size.

2. Cochlear is doing well because it has a global market perspective and as can be seen, Fermiscan is heading in the same direction.

3. Cochlear had very good management of their funding and Fermiscan is also doing a very good job. I actually think in this respect that Fermiscan is doing a better job at cash flow management.

The last thing I want is to have stated that Fermiscan is the next Cochlear because until commercialisation is reached and until the price for the testing has been finalised and tested in initial phases, this company is a mere positive speculation.